Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunomedics Inc.

www.immunomedics.com

Latest From Immunomedics Inc.

Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data

The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.

Clinical Trials Research and Development Strategies

First Filing, In Japan, For Daiichi’s Lead ADC As Others Progress

In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.

Cancer Clinical Trials

Oncology Approvals At US FDA Could Pick Up Over Summer

Only two novel oncologics have cleared the FDA’s approval bar in 2019, but the Pink Sheet’s user fee tracker shows at least eight candidates under review, along with seven significant new indications and formulations.

Approvals Drug Review

Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Deals Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Immunomedics Inc.
  • Senior Management
  • Usama Malik, CFO & CBO
    Brendan Delaney, Chief Commercial Officer
    Morris Rosenberg, CTO
  • Contact Info
  • Immunomedics Inc.
    Phone: (973) 605-8200
    300 The American Rd.
    Morris Plains, NJ 07950
    USA
UsernamePublicRestriction

Register